Krystal Biotech, Inc. has announced its financial results for the third quarter of 2026, revealing impressive growth and a strategic share repurchase program. The company reported global net product revenue of $127.3 million for the quarter, marking a 30% increase compared to the same period last year. This growth is attributed to the continued demand for its product, VYJUVEK, which is used for treating dystrophic epidermolysis bullosa (DEB). The announcement is significant as it highlights Krystal's strong financial position and commitment to returning capital to shareholders.

The results were disclosed in a filing on November 2, 2026, which included details about the company’s operations and financial condition. Krystal Biotech is categorized under the SIC code 2836, which pertains to biological products (no diagnostic substances). The company trades on the Nasdaq under the ticker symbol KRYS.

In the filing, Krystal Biotech emphasized that it has completed pricing negotiations for VYJUVEK in Germany and Italy, with plans to launch in Italy in early 2027. The company also noted that it has secured over 760 reimbursement approvals for VYJUVEK in the United States, supporting its growing patient base. The press release attached to the filing highlighted that the company ended the quarter with a strong balance sheet, boasting $1.2 billion in cash and investments.

Krish S. Krishnan, Chairman and CEO of Krystal Biotech, stated, "Continued growth in VYJUVEK revenue is supporting profitability and funding the advancement of our pipeline. Our financial strength allows us to invest fully in these programs and our global commercial expansion while returning capital to shareholders." The company has authorized a share repurchase program of up to $400 million, which Krishnan described as a reflection of their confidence in the company's long-term growth prospects.

The filing also included a comprehensive overview of the company's ongoing clinical trials. Notably, data from the KB113 clinical trials demonstrated regression in over 80% of assessed basal cell carcinoma lesions in patients with Gorlin syndrome. This promising data could further enhance Krystal's reputation in the biological products sector.

As Krystal Biotech continues to expand its reach, its competitors in the biological products industry will likely be closely monitoring its developments. The company’s focus on innovative therapies and its strong financial results may set a benchmark for others in the field.

Looking ahead, Krystal Biotech is expected to continue its expansion efforts, with ongoing pricing negotiations in multiple European countries and plans for further product launches in Australia and Switzerland. The filing does not specify what other actions may follow this announcement.